

OPEN

Pilot Study of Delayed ICOS/ICOS-L Blockade With α CD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model

Natalie A. O'Neill, MD,¹ Tianshu Zhang, MD, PhD,¹ Gheorghe Braileanu, PhD,¹ Xiangfei Cheng, MD, PhD,¹ Alena Hershfeld, MS,¹ Wenji Sun, MD, PhD,¹ Keith A. Reimann, PhD,² Sia Dahi, MD,¹ Natalia Kubicki, MD,¹ Wessam Hassanein, MD,¹ Christopher Laird, MD,¹ Arielle Cimeno, MD,¹ Agnes M. Azimzadeh, PhD,¹ and Richard N. Pierson, MD^{1,3}

Background. Inducible costimulator (ICOS) is rapidly upregulated with T-cell stimulation and may represent an escape pathway for T-cell costimulation in the setting of CD40/CD154 costimulation blockade. Induction treatment exhibited no efficacy in a primate renal allograft model, but rodent transplant models suggest that the addition of delayed ICOS/ICOS-L blockade may prolong allograft survival and prevent chronic rejection. Here, we ask whether ICOS-Ig treatment, timed to anticipate ICOS upregulation, prolongs NHP cardiac allograft survival or attenuates pathogenic alloimmunity. **Methods.** Cynomolgus monkey heterotopic cardiac allograft recipients were treated with α CD40 (2C10R4, d0-90) either alone or with the addition of delayed ICOS-Ig (d63-110). **Results.** Median allograft survival was similar between ICOS-Ig + α CD40 (120 days, 120-125 days) and α CD40 (124 days, 89-178 days) treated animals, and delayed ICOS-Ig treatment did not prevent allograft rejection in animals with complete CD40 receptor coverage. Although CD4⁺ T_{EM} cells were decreased in peripheral blood (115 ± 24) and mLNs ($49 \pm 1.9\%$) during ICOS-Ig treatment compared with monotherapy ($214 \pm 27\%$, $P = 0.01$; $72 \pm 9.9\%$, $P = 0.01$, respectively), acute and chronic rejection scores and kinetics of alloAb elaboration were similar between groups. **Conclusions.** Delayed ICOS-Ig treatment with the reagent tested is probably ineffective in modulating pathogenic primate alloimmunity in this model.

(*Transplantation Direct* 2018;4: e344; doi: 10.1097/TXD.0000000000000761. Published online 24 January, 2018.)

Costimulation pathway blockade with belatacept is an established alternative therapeutic strategy in clinical transplantation, allowing safe reduction in exposure to nephrotoxic calcineurin inhibitors. Blockade of the CD40/CD154 pathway in preclinical models via α CD40 treatment has demonstrated prolonged allograft survival and delayed production of donor specific antibodies in nonhuman primate (NHP) renal,¹ islet cell,^{2,3} and cardiac⁴ models. However,

α CD40 (or α CD154⁴⁻⁷) monotherapy has been associated with chronic rejection, and a minority of allografts even reject during treatment, identifying existence of rejection mechanisms that are resistant to CD40/CD154-directed costimulation pathway blockade.

Based on prior work by us and others in preclinical models and in man, we hypothesized that immune injury associated with CD40/CD154-directed costimulation blockade is mediated by one of several known alternative costimulation pathways. One pathway of particular interest is the inducible

Received 28 September 2017.

Accepted 21 October 2017.

¹ Department of Surgery, University of Maryland School of Medicine, Baltimore, MD.

² MassBiologics, University of Massachusetts Medical School, Boston, MA.

³ Director Surgical Care, VA Maryland Health Care System, Baltimore, MD.

This work was supported by UO1 AI 066719 (RNP) and the NIH Nonhuman Primate Reagent Resource (KAR) R24 OD010976 and U24 AI126683. Reagents (2C10R4, ICOS-Ig) used in this study were developed and provided by Dr. Keith A. Reimann, DVM and the NIH Nonhuman Primate Reagent Resource (R24 OD010976 and U24 AI126683).

The authors declare no conflicts of interest.

T.Z., X.C., A.M.A., and R.N.P. participated in research design. K.A.R. designed and developed the drugs used in this study. N.A.O. wrote the article, and A.M.A. and R.N.P. critically edited the article. N.A.O., T.Z., G.B., X.C., A.H., W.S., S.D., N.K., W.H., C.L., and A.C. performed all experiments and data analysis.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.transplantationdirect.com).

Correspondence: Richard N. Pierson III, MD, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, 110 South Paca St, 7N-134, Baltimore, MD 21201. (rpierson@som.umaryland.edu).

Copyright © 2018 The Author(s). *Transplantation Direct*. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 2373-8731

DOI: 10.1097/TXD.0000000000000761

costimulator (ICOS)/ICOS-ligand (ICOS-L) pathway. ICOS is rapidly induced after T-cell receptor cross-linking. ICOS is expressed on activated CD4⁺ and CD8⁺ T cells and effector CD4⁺ T follicular helper (Tfh) cells within the germinal center,⁸ enhances T-cell responses to foreign antigens, and ICOS expression is increased in acutely⁹⁻¹¹ and chronically^{5,10,12} rejected allografts. One benefit of ICOS blockade over other costimulation targets may be the pathway's relative specificity for upregulation on activated, pathogenic T cells.

In support of this paradigm, ICOS-Ig monotherapy moderately prolonged allograft survival in mice,^{13,14} and the combination blockade of the CD40/CD154 pathway with ICOS/ICOS-L pathway demonstrated significantly prolonged survival in rodent transplant models.^{10,12,15,16} Murine transplant and autoimmune models have further demonstrated benefit with delayed treatment of ICOS-Ig on both allograft survival, disease pathology, and suppression of CD4⁺ and CD8⁺ effector memory cell populations.^{14,17-20} In contrast, the first NHP preclinical trial of ICOS-Ig, administered for one month (until day 28),²¹ in combination with ongoing CD28/B7 blockade, did not prolong kidney allograft survival. Based on our observation that ICOS expression generally becomes detectable in cynomolgus monkey cardiac allografts about 2 months after transplant, here we evaluate whether delayed ICOS-Ig treatment, timed to anticipate ICOS upregulation in the graft, prolongs allograft survival or attenuates pathogenic alloimmunity in that model.

METHODS

Animal Model

Captive-bred cynomolgus monkeys (*Macaca fascicularis*) of Chinese and Indonesian origin were used. Males weighing 5.0 to 9.5 kg received ABO blood type-compatible hearts from donors that were selected based on stimulation index >5 in mixed lymphocyte reaction to confirm major histocompatibility complex (MHC) class II mismatch. MHC class I mismatch was confirmed retrospectively by detection of anti-donor class I (T cell) alloantibodies, or in exceptional cases where antibody was not detected, by genomic DNA Illumina sequencing.⁴ All protocols were approved by the Institutional Animal Care and Use Committee at the University of Maryland School of Medicine and were conducted in compliance with the National Institutes of Health *Guidelines for the Care and Use of Laboratory Animals*.

Surgical Procedures and Allograft Monitoring

Heterotopic intra-abdominal cardiac transplantation was performed as described previously.²² Cardiac biopsies were obtained by protocol on postoperative days (d) 14, 42, 90, and 150; biopsies were occasionally omitted or delayed due to recipient anemia or weight loss. Mesenteric lymph nodes (mLNs) were usually sampled at the time of biopsy.

Core temperature and graft heart rate, systolic blood pressure, and diastolic blood pressure were assessed at least once daily using intra-abdominal telemetry (D70-PCTP or L11, Data Sciences International, St. Paul, MN) until time of graft explant for failure. Allograft failure was defined by one or more of the following criteria for 2 consecutive days: decline in heart rate greater than 20% below baseline or less than 120 beats per minute, pulse pressure less than 30 mm Hg, or nonpalpable graft contraction.

Immunosuppression

All animals (n = 9) received α CD40 treatment using 2C10R4, a mouse-rhesus IgG4 κ anti-CD40 antibody,² intravenously (IV) at 30 mg/kg on d0, d3, d7, and d14; 10 mg/kg on d21, d28, d35, and d42; and 20 mg/kg on d56 and d84 (total 200 mg/kg). Six animals received α CD40 alone, as previously reported,⁴ and 3 animals additionally received ICOS-Ig, a rhesus recombinant Ig-fusion protein, in combination with α CD40 beginning on d63 (Figure 1). Both 2C10R4 and ICOS-Ig were obtained from NIH Nonhuman Primate Reagent Resource (Boston, MA).

The ICOS-Ig protein, comprising the 141 extracellular amino acids of rhesus ICOS (Genbank accession NM_001266989.1) and the hinge, CH2 and CH3 domains of rhesus IgG1, was expressed using the GPEX $\text{\textcircled{O}}$ technology (Catalent Pharma Solutions, Madison, WI). Briefly, DNA encoding the Ig fusion protein was inserted into an expression vector and Chinese hamster ovary (CHO) cells were transfected with this vector using replication incompetent retrovirus. A pool of transduced CHO cells was grown in serum free medium and ICOS-Ig purified using conventional protein A affinity chromatography. The final product was formulated in PBS, pH 7.0.

ICOS-Ig dosing was progressively adjusted in the 3 animals receiving combination treatment based on interval graft fates and in response to pharmacokinetic data showing low trough levels (Figure 2). The first animal, DV8T, received 5 mg/kg weekly from d63 to d90 (25 mg/kg total). The second animal, DM4XX, received 10 mg/kg on d63, 70; 5 mg/kg on d77, d84, and d90; and 10 mg/kg on d98 and d105 (55 mg/kg). The third animal, DW4P, received 5 mg/kg twice weekly from d63 until d109 (70 mg/kg).

Routine monitoring for CMV was not performed, and antiviral medications were not used.

Drug Trough Levels and CD40 Receptor Coverage

Serum trough α CD40 levels were checked retrospectively by enzyme-linked immunosorbent assay and peripheral blood CD40 receptor saturation was measured by flow cytometry, as described previously.⁴




FIGURE 1. α CD40 and ICOS-Ig dosing schematic. Heterotopic cardiac allograft transplantation in NHP was performed on d0. All animals received α CD40 from d0 to d84 (total of 200 mg/kg). ICOS-Ig (n = 3) was given in a delayed fashion from d63 to d109, and dosing was progressively escalated in each animal. Solid black arrows indicate doses that each animal within the treatment group received. Dotted black arrows indicate additional ICOS-Ig doses given during the dose escalation.




FIGURE 2. Serum ICOS-Ig peak and trough levels. ICOS-Ig treatment was started on d63 in each animal. Solid arrows represent ICOS-Ig doses corresponding to either 5 mg/kg or 10 mg/kg. ICOS-Ig treatment was progressively escalated in each animal from a total of 25 mg/kg (DV8T) to 55 mg/kg (DM4XX) to 70 mg/kg (DW4P). Trough levels were drawn before ICOS-Ig administration intravenously. Peak serum levels were sampled approximately 30 minutes after ICOS-Ig administration. Dotted lines represent time points when either a peak or trough level was not drawn between data points. Serum trough levels (DV8T: 0.9 ± 0.4 , DM4XX: 0.3 ± 0.03 , DW4P: 0.9 ± 0.1 ; one way ANOVA rank $P = 0.03$) and serum peak levels (DV8T: 78 ± 11 , DM4XX: 86 ± 19 , DW4P: 123 ± 10 ; $P = 0.08$) increased with dose escalation. ANOVA, analysis of variance.

Serum peak and trough ICOS-Ig levels were also analyzed retrospectively by enzyme-linked immunosorbent assay. Maxisorp 96-well plates were coated with ICOS-L (ICOSLG Sino Biological Inc, Beijing, China) at $1 \mu\text{g/mL}$ in PBS and were incubated at 4°C overnight. Plates were washed with PBS-Tween 20 0.05% (Sigma-Aldrich, St. Louis, MO), blocked with PBS containing 3% bovine serum albumin (Sigma-Aldrich), and serum samples were incubated followed by goat anti-human IgG secondary antibody and HRP (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA). Due to its inducible nature, reliable flow cytometry methods to detect ICOS receptor coverage have not been developed.

Histological Grading of Acute and Chronic Rejection

Biopsy and explant cardiac tissue specimens were fixed with 10% formalin, processed for paraffin embedding, and stained with hematoxylin and eosin, as described previously.²³ Acute cellular myocardial infiltration was graded using the 2005 International Society for Heart and Lung Transplantation (ISHLT) revised criteria for cardiac allograft rejection.²⁴ Cardiac allograft vasculopathy (CAV) severity with hematoxylin and eosin staining was scored by 3 independent evaluators (N.A.O. or L.B., T.Z., and R.N.P.), who were blinded with respect to treatment group.²³

Lymphocyte Detection and Memory T- and B-Cell Analysis

Routine blood collection was performed per protocol to monitor cell blood counts, B and T lymphocyte subsets, blood chemistry, and antidonor alloantibody (alloAb) production, as previously described.⁴

Peripheral blood was stained for cell surface markers CD3 (clone SP34-2), CD4 PerCP (clone L200), CD8 APC (clone SK1), CD28 (clone 28.2), CD62L (clone SK11), CD45RA (clone 5H9), and CD95 (clone DX2). Samples were collected using FACSCalibur cytometer (BD Biosciences), and data analysis was conducted using FlowJo 10.1r5 (TreeStar, Ashland, OR) software.

Lymph nodes were blocked with pure human IgG (Jackson ImmunoResearch), stained with e780 fixable viability dye

(eBioscience), and then stained with the T-cell surface markers described above and CD20 (clone L27), CD27 (clone MT271), CD38 (clone OKT10), IgD (goat α human; Southern Biotech, Birmingham, AL), and IgM (W6/32, NIH Nonhuman Primate Reagent Resource). CD3⁺ T memory cell phenotypes were defined as naive (T_N) CD45RA⁺CD95⁻CD28⁺CD62L⁺, central memory (T_{CM}) CD45RA⁻CD95⁺CD28⁺CD62L⁺, or effector memory (T_{EM}) CD45RA^{+/-}CD95^{+/-}CD28⁻CD62L⁻.²⁵

CD20⁺ B memory cell phenotypes were defined as naive IgD⁺CD27⁻CD38⁺IgM^{intermediate}, isotype-switched B memory cell CD27⁺IgD⁻, and nonswitched B memory CD27⁺IgD⁺.^{26,27}

alloAb Detection

alloAb was measured retrospectively by flow cytometry using archived frozen donor splenocytes and recipient sera. AlloAb elaboration was defined as consistently detected IgM-positive or IgG-positive donor CD3⁺CD20⁻ T cells greater than 10% relative to donor serum before transplant, as described previously.²³

Statistical Analysis

Survival analysis was performed by the Kaplan-Meier method and compared using the log-rank test. Continuous variables were expressed as the mean \pm standard error of the mean (SEM) or median and interquartile ranges, and these were compared using either the 2-tailed Mann-Whitney U test to compare 2 groups or 1-way analysis of variance on ranks for comparing 3 or more groups. Nominal variables were compared using a contingency table and the Fisher exact test. P values less than 0.05 were considered statistically significant. All statistical analyses were performed on a personal computer with GraphPad InStat (version 3.01; GraphPad Software, San Diego, CA).

RESULTS

ICOS-Ig Dose Escalation

For the αCD40 + ICOS-Ig-treated animals, serum ICOS-Ig levels were analyzed retrospectively to determine serum drug levels before and 30 minutes after ICOS-Ig dosing. Although peak levels (mean \pm SEM $78 \pm 11 \mu\text{g/mL}$) achieved




FIGURE 3. Kaplan-Meier allograft survival curve. Graft rejection was defined by one or more of the following criteria for 2 consecutive days: decline in heart rate >20% below baseline or <120 beats per minute, pulse pressure <30 mm Hg, or nonpalpable graft contraction. MST is similar between the 2 treatment groups. (+) represent allografts removed without evidence of rejection, and are censored from survival analyses. α CD40 (d0-d84) and ICOS-Ig (d63-d109) treatment time periods are denoted with arrows. α CD40 monotherapy control group was previously reported.⁴

our expected target (>50 μ g/mL), ICOS-Ig serum trough levels in the first animal, DV8T (0.9 ± 0.4 μ g/mL) were lower than anticipated. Given this observation, ICOS-Ig dosing was escalated for subsequent animals (Figure 2). Although peak levels increased proportionate to the administered dose after each infusion, trough levels remained lower than expected (DW4P: 0.9 ± 0.1 μ g/mL; $P = 0.03$). These results suggest that the half-life of this molecule was shorter than expected.

Allograft Survival

Median survival time (MST) of the combination α CD40 + ICOS-Ig-treated animals ($n = 3$, MST 120 days; range, 120-125) was similar to α CD40 monotherapy ($n = 6$, 124, 89-178; $P = 0.6$, Figure 3). Specifically, ICOS-Ig treatment did not have a measureable effect on allograft survival. Two animals in the 2C10R4 treatment group (FB9N and DV36) had functional, beating allografts removed for health reasons (Table 1), as reported previously.⁴

Before α CD40 re-dosing, CD40 receptor coverage was regularly assessed. CD40 receptor coverage was nearly 100% for

TABLE 1. Individual animal survival and receptor coverage at time of allograft explant

Treatment groups	Animal ID	Allograft survival (d)	Receptor coverage (%) ^a
α CD40	FB9N	>25	100
	DV36	>69	100
	FC9J	89	88
	FA53	117	100
	DV2R	130	48
	FB6E	178	0
α CD40 + ICOS-Ig	DW4P	120	100
	DM4XX	120	99
	DV8T	125	17

Animals with adequate CD40 receptor coverage at the time of explant (FA53, DW4P, DM4XX) may represent costimulation blockade resistant rejection. Shaded boxes represent animals with functional, beating allografts removed for other health reasons.

^a CD40 receptor coverage at the time of allograft explant.

at least 35 days after the final α CD40 treatment, and similar between α CD40 alone ($98.8 \pm 0.8\%$ on d118) and α CD40 + ICOS-Ig ($99.0 \pm 1.0\%$ on d118, $P = 0.8$; Figure 4). One of 4 evaluable animals in the α CD40-treatment group (FA53) and 2 of 3 animals in the combination group (DM4XX and DW4P) exhibited graft rejection despite 100% receptor coverage (Table 1). These data demonstrate existence of graft injury mechanisms escaping control by CD40-directed treatment, alone or with ICOS-Ig, despite persistent, prevalent CD40 receptor coverage.

Acute and Chronic Rejection Acute Cellular Infiltration

Protocol biopsies and explanted cardiac allografts were evaluated for evidence of acute and chronic rejection, and time points were grouped by α CD40 alone (d0-60 for both groups), during treatment with ICOS-Ig (d61-110), or after ICOS-Ig treatment (d111-180). Acute cellular infiltration graded by ISHLT score²⁴ was similar between α CD40 monotherapy and α CD40 + ICOS-Ig-treated animals at each time point (Figure 5A). Chronic allograft vasculopathy (CAV) severity was also similar at each time point between the 2 groups (Figure 5B). These data demonstrate participation of both acute (cellular) and chronic (as CAV) rejection mechanisms that escape control by CD40-directed treatment and are not modulated by ICOS-Ig as administered.

alloAb Production

Because others have shown that α ICOS inhibits alloAb isotype switching,¹⁶ we evaluated IgM and IgG alloAb production after transplantation. IgM alloAb elaboration from d0 to d60 was significantly higher in the α CD40 + ICOS-Ig (7 of 22 time points with IgM alloAb >10%; $P = 0.0004$) than the α CD40 monotherapy treatment group (0 of 38) because one animal (DV8T) within the α CD40 + ICOS-Ig group developed IgM antidonor alloAb on d7 (d7-118 mean \pm SEM: $18 \pm 1.4\%$; Figure 6).

During ICOS treatment (d61-110) and after ICOS treatment (d111-180), IgM and IgG alloAb detection was similar between the 2 groups and elaboration occurred just prior or at the time of allograft rejection. Together, these data demonstrate participation of humoral (as anti-donor alloantibody) rejection mechanisms that escape control by CD40-directed




FIGURE 4. Mean peripheral blood CD40 receptor coverage (%) detected by flow cytometry. SEM is demonstrated in error bars. Solid arrows represent α CD40 dosing. Receptor coverage was nearly 100% through d118, after which point coverage becomes somewhat variable across animals.




FIGURE 5. Acute and chronic rejection histology grading of protocol biopsies and explanted allografts shown as box and whisker plots. From d0 to d60, both experimental groups received only α CD40. From d61 to d100, the combination group (black) received α CD40 + ICOS-Ig. A, Median ISHLT acute cellular infiltration score was similar between the 2 groups. B, Median CAV, a measure of chronic rejection, severity scores were also similar between both groups. Outlier data points are shown as dots.

treatment and suggest that the addition of delayed ICOS-Ig treatment, as administered, was unable to prevent alloAb isotype switching.

mLN Memory B-Cell Prevalence

Given the failure of ICOS-Ig treatment to prevent alloAb isotype switch, we evaluated the prevalence of memory B cells in mLN after ICOS-Ig treatment. The proportion of naive B cells detected by flow cytometry within lymph node was similar between the 2 groups (Figure 7 and SDC Figure S1, <http://links.lww.com/TXD/A57>). The proportion of isotype-switch memory B cells significantly increased in the α CD40 + ICOS-Ig-treated animals in mLN from d90 and d120 ($42 \pm 9.1\%$) compared with α CD40-treated animals ($5.8 \pm 1.1\%$; $P = 0.04$), and, reciprocally, nonisotype switched memory B cells trended down in the combination group ($2.0 \pm 0.6\%$ vs. $8.0 \pm 2.3\%$; $P = 0.07$). Together with the alloAb data, delayed ICOS-Ig treatment did not prevent development of isotype switched memory B cells within the regional lymph node and subsequent humoral rejection.

Memory T Cell Kinetics in Blood and Lymph Nodes

Several murine models have demonstrated a decrease in T_{EM} cells with disruption of the ICOS/ICOS-L pathway,^{14,28} which prompted us to study the kinetics of T_N , T_{CM} , and

T_{EM} cells in peripheral blood. From d70 to d130, time points during and after ICOS-Ig treatment, $CD4^+$ T_{EM} cells were significantly lower in the α CD40 + ICOS-Ig animals (115 ± 24 cells/ μ L blood) compared with α CD40-treated animals (214 ± 27 ; $P = 0.01$), and a similar trend was observed in the $CD8^+$ T_{EM} cells (527 ± 60 vs. 736 ± 120 ; Figure 8 and SDC Figure S2, <http://links.lww.com/TXD/A58>). $CD8^+$ T_{CM} cells were significantly higher in the α CD40 + ICOS-Ig group (102 ± 8) than in α CD40 monotherapy (65 ± 5 ; $P = 0.0004$); however, this cell population was also elevated from d0 to d65 in the combination group (83 ± 7) than in the α CD40 monotherapy group (50 ± 5 ; $P = 0.0001$).

Similarly, $CD4^+$ T_{EM} cell comprised a significantly lower proportion of $CD4^+$ cells in mLN in association with ongoing ICOS-Ig treatment ($49 \pm 1.9\%$ at d90 and d120) compared to α CD40 monotherapy ($72 \pm 9.9\%$; $P = 0.01$, Figure 9 and SDC Figure S3, <http://links.lww.com/TXD/A59>). This relative decrease in the mLN $CD4^+$ T_{EM} cell population was accompanied by a relative increase in $CD4^+$ T_N proportion (45 ± 1.4 vs. $21 \pm 6.3\%$; $P = 0.002$), whereas $CD4^+$ T_{CM} proportions remained stable and similar between the 2 groups. These results suggest that ICOS-Ig treatment significantly skews the $CD4^+$ T_{EM} cell trafficking in blood and secondary lymphatic compartments, as expected based on rodent studies.

DISCUSSION

ICOS was discovered as a CD28-homologous structure expressed on activated T cells. ICOS is absent on naive T cells but is rapidly upregulated on both $CD4^+$ and $CD8^+$ T cells after T cell receptor cross-linking. CD28 ligation augments ICOS expression, but is not necessarily required.^{29,30} Its ligand, ICOS-L (B7RP-1, B7h, GL50),^{9,31} is constitutively expressed on B cells and immature dendritic cells (DC). ICOS-L expression is induced on monocytes, macrophages, and other non-hematopoietic cells like fibroblasts and endothelial cells after inflammatory stimuli.^{12,32,33}

The ICOS/ICOS-L pathway appears to play a nonredundant role in T-cell costimulation, proliferation, and expansion.^{34,35} ICOS enhances T-cell response to an antigen by increasing cytokines such as IL-5, TNF- α , IFN- γ ,^{12,29,31,36} and Th2 cytokines IL-4^{29,37} and IL-10.^{9,12} ICOS also appears to play a role in chemokine receptors CCR1, CCR2, CCR5, CXCR3, CXCR4, and CXCR5 expression.^{12,38,39} Together, these cytokines and chemokines are induced upon T-cell activation and play a role in allograft rejection. These considerations justify efforts to explore blockade of the ICOS/ICOS-L pathway to prevent alloimmune injury in transplantation.

Early ICOS blockade (α ICOS or α ICOS-L) in murine cardiac¹³⁻¹⁵ or hepatic⁴⁰ transplant models found that early treatment, initiating on d0, was associated with a modest, though significant, increase in allograft survival compared to untreated controls; however, survival was similar between untreated controls and ICOS-Ig-treated NHP.²¹ In autoimmune mouse models of EAE, asthma, and diabetes, early α ICOS treatment during the antigen priming phase was found to increase the severity of disease, cell infiltration, and damaging cytokine expression.^{17,18,41} When α ICOS treatment was delayed and given after T-cell activation, clinical disease was abrogated at the clinical and cellular level.^{17,18} Delayed blockade of the ICOS/ICOS-L pathway in mouse cardiac models significantly prolonged allograft survival and decreased cellular infiltration,




FIGURE 6. Anti-donor alloantibody production after transplantation. The last data point for each animal represents the time of allograft explant. IgG alloAb elaboration was attenuated in both groups until the time of allograft rejection.

vasculopathy severity, and IgG alloAb production.^{14,19,20} Given these encouraging results, we chose to evaluate delayed ICOS-Ig treatment in a MHC mismatched cardiac allograft NHP model.

Efficacy appears to be most consistent when the ICOS/ICOS-L pathway is targeted in conjunction with CD40/154 pathway blockade^{10,12,15} whereas heterogeneous results,^{10,13,20,21,42} including deleterious effects with shorter graft survival,^{14,43} have been reported when ICOS/ICOS-L targeting is combined with α CD28/B7 blockade. These considerations informed our current experimental design, and we chose to combine delayed ICOS-Ig with α CD40, rather than calcineurin inhibition or α CD154, based on several considerations. In our NHP model, α CD40 consistently prolongs allograft survival as a monotherapy during treatment, with reproducible detection of ICOS at around 60 days, followed by progressive chronic rejection leading to graft loss.⁴ In contrast,

either 5C8H1 or cyclosporine A are associated with failure of some grafts during treatment^{4,5,23} and inconsistent kinetics of first ICOS detection by PCR and IHC (AA, unpublished observations). However, our resulting pilot data suggest that delayed ICOS-Ig, as applied here, does not significantly attenuate cardiac allograft rejection mechanisms associated with α CD40 costimulation blockade.

T cells expressing ICOS are phenotypically resting or T_{EM} cells,^{9,28,31,39} and these ICOS⁺ T memory cells can undergo rapid expansion independent of CD28/B7 or CD40/CD154 ligation.⁴⁴ As predicted from ICOS-deficient human and mice,^{28,39} in this study ICOS-Ig treatment demonstrated a decrease of CD4⁺ T_{EM} cells in peripheral blood and mLNs during treatment. In contrast to rodent studies,^{14,15} the decrease of T_{EM} cells in our study did not affect allograft survival or acute or chronic rejection after transplantation, which may be due to intact cytotoxic CD8⁺ T cell responses of the




FIGURE 7. mLN B memory cell phenotype by flow cytometry with α CD40 alone (grey) or α CD40 + ICOS-Ig (black). Lymph nodes from protocol biopsies on d90 and d120 represent samples after delayed ICOS-Ig treatment. Naïve B cells were defined as CD20⁺IgD⁺CD27⁻CD38⁺IgM^{intermediate}, nonswitched (NS) B memory CD20⁺CD27⁺IgD⁺, and isotype-switched (IS) B memory cell CD20⁺CD27⁺IgD⁻. After ICOS-Ig treatment, IS B memory proportion significantly increased ($42 \pm 9.1\%$). NS B memory trended downward ($2.0 \pm 0.6\%$), and naïve B cells were similar ($5.7 \pm 2.4\%$) compared with α CD40 monotherapy ($5.8 \pm 1.1\%$, $8.0 \pm 2.3\%$, $23 \pm 17\%$, respectively). Light grey lines represent the mean. ** $P = 0.04$.




FIGURE 8. Peripheral blood T memory cell kinetics after transplantation. CD3⁺CD4⁺ and CD8⁺ T cells were identified using flow cytometry. T memory cell phenotypes were characterized as naive (N: CD45RA⁺CD62L⁺CD28⁺ or CD95⁻CD62L⁺CD28⁺), T_{CM} (CD45RA⁻CD62L⁺CD28⁺ or CD95⁺CD62L⁺CD28⁺), or T_{EM} cell (CD45RA^{+/}-CD62L⁻CD28⁻ or CD95^{+/}-CD62L⁻CD28⁻). During ICOS-Ig treatment (black, n = 3), CD4⁺ T_{EM} cells significantly decreased compared to αCD40 monotherapy (grey, n = 6). No significant difference was seen in the CD8⁺ T_{EM} phenotype. SEM is demonstrated in error bars. **P* = 0.01, ***P* = 0.0004.

remaining T_{EM} cell,¹⁰ CD8⁺ICOS⁺ T_{EM} cells that divide within the allograft after crossing the endothelial barrier,⁴⁵ or the loss of inhibitory effector functions of regulatory T cells, which is dependent on ICOS/ICOS-L signaling.^{18,28,41} Our results do not provide compelling evidence regarding any of these nonexclusive hypotheses.

ICOS expression within lymph nodes is predominately on Tfh cells within the germinal center where T cells induce the terminal differentiation patterns of B cells into plasma or memory cells.^{8,9,46,47} Although we did see a similar effect of ICOS-Ig on T_{EM} cell phenotype in mLN as has been described in mice, we did not observe a difference in IgM alloAb development or IgG alloAb class switch between αCD40 and combination ICOS-Ig + αCD40-treated NHP. Failure to modulate class switching was unexpected, as others have demonstrated limited alloAb isotype switching with disruption of ICOS/ICOS-L.^{16,36,37} Furthermore, ICOS-deficient mice and human have reduced Tfh (CD4⁺CXCR5⁺) cells³⁹ suggesting B memory cells may be affected by ICOS; however, we found an increased proportion of isotype switch B memory cells after ICOS-Ig treatment within regional lymph nodes. The continued persistence of B memory cells and ability to produce alloAb likely contributed to the ineffectiveness of ICOS-Ig in our study, although we cannot exclude the possibility that either the dose or pharmacologic characteristics of our molecule were inadequate to efficiently block the ICOS/ICOS-L pathway *in vivo*.⁴⁸

The lack of synergistic effects with delayed ICOS-Ig in this NHP study compared with previous rodent studies may be due to several other factors. The reagent target itself, ICOS-Ig, combines with its ligand on APC, preventing ligation of ICOS on T cells, whereas αICOS binds the ICOS receptor on T cells, potentially leading directly to effects on the ICOS-expressing T-cell population. Although an ICOS-Ig for human use is not currently available,⁴⁹ 2 different αICOS monoclonal antibodies, MEDI-570 (ClinicalTrials.gov Identifier: NCT01127321 and NCT02520791) and AMG 557 (ClinicalTrials.gov Identifier: MCT02334306),⁵⁰ are in phase 1 and phase 2, respectively, clinical trials for SLE, Sjögren's syndrome, and refractory T-cell lymphoma. Alternatively, the ICOS-Ig dose may not have been sufficiently intensive to saturate the pervasive constitutive expression of ICOS-L on APC and nonhematopoietic cells. This interpretation is supported by the dose escalation that was required¹⁵ to demonstrate modest survival improvement reported in a similar model,⁴² and our inability to achieve increased ICOS-Ig trough levels despite dose escalation. Finally, the most sensitive method to detect ICOS expression remains unclear, and, therefore, the optimal timing of delayed ICOS-Ig treatment may not have been achieved in this study.

In summary, this pilot study of delayed ICOS-Ig treatment in combination with αCD40 failed to prolong primate cardiac allograft survival, or to significantly modulate acute rejection, chronic rejection, or alloAb elaboration, despite an




FIGURE 9. mLN T memory cell phenotype by flow cytometry with α CD40 alone (grey) or α CD40 + ICOS-Ig (black). Lymph nodes from protocol biopsies on d90 and d120 represent samples after delayed ICOS-Ig treatment. The proportion of $CD3^+CD4^+$ (top row) and $CD3^+CD8^+$ (bottom row) T_{EM} cell phenotypes were defined as N ($CD45RA^+CD62L^+CD28^+$ or $CD95^-CD62L^+CD28^+$), T_{CM} ($CD45RA^-CD62L^+CD28^+$ or $CD95^+CD62L^+CD28^+$), or T_{EM} cell ($CD45RA^{+/}CD62L^-CD28^-$ or $CD95^{+/}CD62L^-CD28^-$). After ICOS-Ig treatment, LN $CD4^+ T_{EM}$ cells ($49.1 \pm 1.9\%$) significantly decreased compared to α CD40 monotherapy (grey, $71.7 \pm 9.9\%$). Light grey lines represent the mean. ** $P = 0.002$, * $P = 0.01$.

observed decrease in T_{EM} cell in blood and lymph nodes during treatment. Together with the pilot study results from Lo et al. showing similar allograft results with early ICOS-Ig treatment with CTLA-4Ig, we provisionally conclude that ICOS-Ig, as tested, is ineffective in preventing costimulation blockade resistant rejection. Although a reagent with improved pharmacodynamics or demonstrated efficacy in another model would arguably justify reconsideration in transplantation, our future study regarding mechanisms to better protect grafts in recipients treated with costimulation blockade will focus on alternative pathways.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Ivan Tatarov, DVM, Dr. Elana Rybak, DVM, Evelyn Sievert, Dawn Parsell, Elizabeth Kang, Andrea Gatling, and Kathryn Thomas for their assistance with data collection and animal care. The authors also would like to thank Dr. Lars Burdorf, MD for his assistance with histology scoring.

REFERENCES

- Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. *Am J Transplant.* 2014;14:59–69.
- Lowe M, Badell IR, Thompson P, et al. A novel monoclonal antibody to CD40 prolongs islet allograft survival. *Am J Transplant.* 2012;12:2079–2087.
- Oura T, Hotta K, Lei J, et al. Immunosuppression with CD40 costimulatory blockade plus rapamycin for simultaneous islet-kidney transplantation in nonhuman primates. *Am J Transplant.* 2017;17:646–656.
- O'Neill NA, Zhang T, Braileanu G, et al. Comparative evaluation of α CD40 (2C10R4) and α CD154 (5C8H1 and IDEC-131) in a nonhuman primate cardiac allotransplant model. *Transplantation.* 2017;101:2038–2047.
- Azizzadeh AM, Pfeiffer S, Wu G, et al. Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms. *Transplantation.* 2006;81:255–264.
- Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. *Nat Med.* 1999;5:686–693.
- Kanmaz T, Fechner JJ Jr, Torrealba J, et al. Monotherapy with the novel human anti-CD154 monoclonal antibody AB1793 in rhesus monkey renal transplantation model. *Transplantation.* 2004;77:914–920.
- Linterman MA, Rigby RJ, Wong R, et al. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. *Immunity.* 2009;30:228–241.
- Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. *Nature.* 1999;397:263–266.
- Nanji SA, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. *Am J Transplant.* 2004;4:526–536.
- Watanabe M, Hara Y, Tanabe K, et al. A distinct role for ICOS-mediated co-stimulatory signaling in $CD4^+$ and $CD8^+$ T cell subsets. *Int Immunol.* 2005;17:269–278.
- Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. *Nat Immunol.* 2001;2:591–596.
- Kosuge H, Suzuki J, Gotoh R, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. *Transplantation.* 2003;75:1374–1379.
- Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. *J Clin Invest.* 2003;112:234–243.
- Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. *Transplantation.* 2005;80:255–263.

16. Zhang QW, Rabant M, Schenk A, et al. ICOS-Dependent and -independent functions of memory CD4 T cells in allograft rejection. *Am J Transplant.* 2008;8:497–506.
17. Rottman JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. *Nat Immunol.* 2001;2:605–611.
18. Herman AE, Freeman GJ, Mathis D, et al. CD4 + CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. *J Exp Med.* 2004;199:1479–1489.
19. Kashizuka H, Sho M, Nomi T, et al. Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. *Transplantation.* 2005;79:1045–1050.
20. Pan XC, Guo L, Deng YB, et al. Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection. *Surg Today.* 2008;38:815–825.
21. Lo DJ, Anderson DJ, Song M, et al. A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation. *Am J Transplant.* 2015;15:984–992.
22. Pierson RN 3rd, Chang AC, Blum MG, et al. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. *Transplantation.* 1999;68:1800–1805.
23. Kelishadi SS, Azimzadeh AM, Zhang T, et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. *J Clin Invest.* 2010;120:1275–1284.
24. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant.* 2005;24:1710–1720.
25. Nadazdin O, Boskovic S, Murakami T, et al. Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys. *Am J Transplant.* 2010;10:1375–1384.
26. Kuhrt D, Faith S, Hatterer A, et al. Naïve and memory B cells in the rhesus macaque can be differentiated by surface expression of CD27 and have differential responses to CD40 ligation. *J Immunol Methods.* 2011;363:166–176.
27. Wu YC, Kipling D, Dunn-Walters DK. The relationship between CD27 negative and positive B cell populations in human peripheral blood. *Front Immunol.* 2011;2:81.
28. Burmeister Y, Lischke T, Dahler AC, et al. ICOS controls the pool size of effector-memory and regulatory T cells. *J Immunol.* 2008;180:774–782.
29. McAdam AJ, Chang TT, Lumelsky AE, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. *J Immunol.* 2000;165:5035–5040.
30. Riley JL, Blair PJ, Musser JT, et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. *J Immunol.* 2001;166:4943–4948.
31. Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. *Nature.* 1999;402:827–832.
32. Liang L, Porter EM, Sha WC. Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling. *J Exp Med.* 2002;196:97–108.
33. van Berkel ME, Schrijver EH, Hoffhuis FM, et al. ICOS contributes to T cell expansion in CTLA-4 deficient mice. *J Immunol.* 2005;175:182–188.
34. van Berkel ME, Oosterwegel MA. CD28 and ICOS: similar or separate costimulators of T cells? *Immunol Lett.* 2006;105:115–122.
35. Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: friend or foe? *Front Immunol.* 2016;7:304.
36. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. *Nature.* 2001;409:102–105.
37. Tafuri A, Shahinian A, Blatt F, et al. ICOS is essential for effective T-helper-cell responses. *Nature.* 2001;409:105–109.
38. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. *J Exp Med.* 2000;192:1515–1520.
39. Bossaller L, Burger J, Draeger R, et al. ICOS deficiency is associated with a severe reduction of CXCR5 + CD4 germinal center Th cells. *J Immunol.* 2006;177:4927–4932.
40. Guo L, Li XK, Funeshima N, et al. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). *Transplantation.* 2002;73:1027–1032.
41. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. *Nat Med.* 2002;8:1024–1032.
42. Guo L, Fujino M, Kimura H, et al. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. *Transpl Immunol.* 2003;12:41–48.
43. Salama AD, Yuan X, Nayer A, et al. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. *Am J Transplant.* 2003;3:390–395.
44. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. *J Immunol.* 2000;164:265–272.
45. Schenk AD, Gorbacheva V, Rabant M, et al. Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. *Am J Transplant.* 2009;9:64–73.
46. Bernard D, Hansen JD, Du Pasquier L, et al. Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 and multiple BTLAs. *Dev Comp Immunol.* 2007;31:255–271.
47. Xu H, Li X, Liu D, et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. *Nature.* 2013;496:523–527.
48. Harvey C, Elpek K, Duong E, et al. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. *J Immunother Cancer.* 2015;3(Suppl2):O9.
49. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. *Nat Rev Drug Discov.* 2013;12:130–146.
50. Sullivan BA, Tsuji W, Kivitz A, et al. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. *Lupus Sci Med.* 2016;3:e000146-2016-000146. eCollection 2016.